SK바이오팜, 1분기 매출 2279억원…전년 동기 대비 58% 증가

SK Biopharm demonstrates strong Q1 momentum with revenues up 58% year-over-year and operating profit surging 250%, signaling successful commercialization of its pipeline products. This exceptional profit expansion indicates the company is transitioning from R&D-heavy investments to profitable operations, a critical milestone for Korean biotech sector competitiveness and investor confidence.